deltatrials
Completed PHASE2 NCT01163396

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer

Sponsor: Gruppo Oncologico del Nord-Ovest

Conditions Colorectal Cancer Metastatic
Interventions 5-fluorouracil/leucovorin Bevacizumab Irinotecan Oxaliplatin
Updated 5 times since 2017 Last updated: Mar 10, 2015 Started: Jul 31, 2007 Primary completion: Apr 30, 2009 Completion: Apr 30, 2010

Listed as NCT01163396, this PHASE2 trial focuses on Colorectal Cancer Metastatic and remains completed. Sponsored by Gruppo Oncologico del Nord-Ovest, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gruppo Oncologico del Nord-Ovest
Data source: Gruppo Oncologico del Nord-Ovest

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.